Toward precision medicine: TBC1D4 disruption is common among the inuit and leads to underdiagnosis of type 2 diabetes

Diabetes Care

Volumn 39, Issue 11, 2016, Pages 1889-1895

  Manousaki, Despoina ^a,b   Kent, Jack W ^c   Haack, Karin ^c   Zhou, Sirui ^b,d   Xie, Pingxing ^b,e   Greenwood, Celia M ^a,b   Brassard, Paul ^a,b   Newman, Deborah E ^c   Cole, Shelley ^c   Umans, Jason G ^f,g   Rouleau, Guy ^b,e   Comuzzie, Anthony G ^c   Richards, J Brent ^a,b,h  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f MEDSTAR RESEARCH INSTITUTE   (United States)

^g DC   (United States)

^h KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENE; GENE DISRUPTION; GENE FREQUENCY; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HETEROZYGOTE DETECTION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INUIT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONSENSE MUTATION; PERSONALIZED MEDICINE; POPULATION GENETICS; PREVALENCE; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TBC1D4 GENE; ALASKA; CANADA; DIABETES MELLITUS, TYPE 2; DNA SEQUENCE; GENETICS; GLUCOSE TOLERANCE TEST; GREENLAND; HYPERGLYCEMIA; METABOLISM; MIDDLE AGED; POSTPRANDIAL STATE; PREDIABETIC STATE; STOP CODON;

GLUCOSE BLOOD LEVEL; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; INSULIN; STOP CODON; TBC1D4 PROTEIN, HUMAN;

ALASKA; BLOOD GLUCOSE; CANADA; CODON, NONSENSE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE TOLERANCE TEST; GREENLAND; GTPASE-ACTIVATING PROTEINS; HUMANS; HYPERGLYCEMIA; INSULIN; INUITS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; PRECISION MEDICINE; PREDIABETIC STATE; SEQUENCE ANALYSIS, DNA;

EID: 84994381404     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-0769     Document Type: Article

References (30)

1. Hudson KLR, Patrick-Lake B, Burchard EG, et al.; Precision Medicine Initiative (PMI) Working Group. The Precision Medicine Initiative Cohort Program-Building a Research Foundation for 21st Century Medicine. Bethesda, MD, National Institutes of Health, 2015
2. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015;372:793-795
3. Moltke I, Grarup N, Jørgensen ME, et al. A common Greenlandic TBC1D4 variant confers muscle insulin resistance and type 2 diabetes. Nature 2014;512:190-193
4. Jørgensen ME, Bjeregaard P, Borch-Johnsen K. Diabetes and impaired glucose tolerance among the inuit population of Greenland. Diabetes Care 2002;25:1766-1771
5. Helgason A, Pálsson G, Pedersen HS, et al. mtDNA variation in Inuit populations of Greenland and Canada: migration history and population structure. Am J Phys Anthropol 2006;130: 123-134
6. Howard BV, Devereux RB, Cole SA, et al. A genetic and epidemiologic study of cardiovascular disease in Alaska natives (GOCADAN): design and methods. Int J Circumpolar Health 2005;64: 206-221
7. Zhou S, Xiong L, Xie P, et al. Increased missense mutation burden of fatty acid metabolism related genes in Nunavik Inuit population. PLoS One 2015;10:e0128255
8. Abecasis GR, Altshuler D, Auton A, et al.; 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing [published correction appears in Nature 2011;473:544]. Nature 2010;467:1061-1073
9. Gutt M, Davis CL, Spitzer SB, et al. Validation of the insulin sensitivity index (ISI(0,120)): comparison with other measures. Diabetes Res Clin Pract 2000;47:177-184
10. Blangero J, Goring HH, Kent JW Jr, et al. Quantitative trait nucleotide analysis using Bayesian model selection. Hum Biol 2005;77: 541-559
11. Almasy L, Blangero J.Multipoint quantitativetrait linkage analysis in general pedigrees. Am J Hum Genet 1998;62:1198-1211
12. Gelman A, Hill J, YajimaM.Why we (usually) don't have to worry about multiple comparisons. J Res Educ Eff 2012;5:189-211
13. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(Suppl. 1):S62-S69
14. Mehta CR, Patel NR. A hybrid algorithm for Fishers exact test in unordered rxc contingencytables. Commun Stat Theory Methods 1986;15: 387-403
15. Clarkson DB, Fan YA, Joe H. A remark on algorithm-643-Fexact-an algorithm for performing Fishers exact test in R X C contingencytables. ACM Trans Math Software 1993;19: 484-488
16. Wilson SE, Lipscombe LL, Rosella LC, Manuel DG. Trends in laboratory testing for diabetes in Ontario, Canada 1995-2005: A population-based study. BMC Health Serv Res 2009; 9:41
17. Sano H, Kane S, Sano E, et al. Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation. J Biol Chem 2003; 278:14599-14602
18. Wang HY, Ducommun S, Quan C, et al. AS160 deficiency causes whole-body insulin resistance via composite effects in multiple tissues. Biochem J 2013;449:479-489
19. Dash S, Sano H, Rochford JJ, et al. A truncationmutation in TBC1D4 in a family with acanthosis nigricans and postprandial hyperinsulinemia. Proc Natl Acad Sci U S A 2009;106:9350-9355
20. DECODE Study Group. Age-and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care 2003;26:61-69
21. Sorkin JD, Muller DC, Fleg JL, Andres R. The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality: data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. Diabetes Care 2005;28:2626-2632
22. Cavalot F, Pagliarino A, Valle M, et al. Postprandial blood glucose predicts cardiovascular events and all-causemortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study. Diabetes Care 2011;34:2237-2243
23. Sarwar N, Gao P, Seshasai SR, et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative metaanalysis of 102 prospective studies [published correction appears in Lancet 2010;376:958]. Lancet 2010;375:2215-2222
24. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003;27(Suppl. 2):S10-S13
25. Carter EA, MacCluer JW, Dyke B, et al. Diabetes mellitus and impaired fasting glucose in Alaska Eskimos: The Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN) study. Diabetologia 2006;49:29-35
26. Pelletier C, Dai S, Roberts KC, Bienek A, Onysko J, Pelletier L. Report summary. Diabetes in Canada: facts and figures from a public health perspective. Chronic Dis Inj Can 2012; 33:53-54
27. Simmons RK, Echouffo-Tcheugui JB, Griffin SJ. Screening for type 2 diabetes: an update of the evidence. Diabetes Obes Metab 2010;12: 838-844
28. Li L, Hamel N, Baker K, et al. A homozygous PMS2 founder mutation with an attenuated constitutional mismatch repair deficiency phenotype. J Med Genet 2015;52:348-352
29. Della-Morte D, Palmirotta R, Rehni AK, et al. Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors. Pharmacogenomics 2014; 15:2063-2082
30. Soccio RE, Chen ER, Lazar MA. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab 2014;20:573-591